Randomized Comparison of Cangrelor, Tirofiban and Prasugrel in Patients With STEMI Referred for Primary PCI.
Status:
Completed
Trial end date:
2019-12-27
Target enrollment:
Participant gender:
Summary
Primary percutaneous coronary intervention (PCI) is the main reperfusion therapy in patients
with ST-elevation myocardial infarction (STEMI). The optimal platelet inhibition at the time
of PCI is fundamental, however, the comparative speed of action of cangrelor as opposed to
tirofiban and to chewed or integer loading dose of prasugrel is unknown.
The purpose of this trial is to assess the inhibition of platelet aggregation with different
regimens on platelet inhibition (tirofiban bolus+infusion, cangrelor bolus+infusion,
prasugrel chewed loading dose, prasugrel integer loading dose) in the early phase of primary
PCI.